Planning Underway for Phase 3 Development of Tezepelumab in COPD THOUSAND OAKS, Calif., April 16, 2024 /PRNewswire/ — Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease…